Results 1 to 10 of about 4,836 (234)

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan

Journal of Microbiology, Immunology and Infection, 2022
Background: Imipenem-relebactam is a new β-lactam and β-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However, difference in carbapenem resistant mechanisms existed with geographic variations. Objective:
Tsung-Ying Yang, Ya-Ju Hsieh, Liang-Chun Wang   +2 more
exaly   +5 more sources

In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates [PDF]

Antibiotics
Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Alejandro Seoane-Estévez, Pablo Aja-Macaya, Andrea Garcia-Pose, Paula López-Roa, Alba Ruedas-López, Verónica Gonzalez-Galán, Jaime Esteban, Jorge Arca-Suárez, Martín Pampín, Alejandro Beceiro, Marina Oviaño, Germán Bou, on behalf of the GEIM-SEIMC Study Group   +12 more
doaj   +3 more sources

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS [PDF]

Journal of Clinical Microbiology
Pseudomonas aeruginosa is a major nosocomial pathogen commonly involved in multidrug-resistant (MDR) infections that are very difficult to treat. Imipenem/relebactam is a new carbapenem/β-lactamase inhibitor combination with robust activity against P ...
Ana Candela, María Fernández-Billón, Pablo Aja-Macaya, Lucía González-Pinto, Pablo Arturo Fraile-Ribot, Esther Viedma, Isaac Alonso-García, Tania Blanco-Martín, Roberto Estévez-Alfaya, Ana Fernández-González, Alejandro Beceiro, Carla López-Causapé, Marina Oviaño, Germán Bou, Antonio Oliver, Jorge Arca-Suárez   +15 more
doaj   +3 more sources

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus [PDF]

Antibiotics
Background: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and ...
Madeline Sanders, Sun Woo Kim, Aditi Shinde, Danielle Fletcher-Williams, Eric Quach, Paul Beringer   +5 more
doaj   +3 more sources

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies) [PDF]

Microbiology Spectrum, 2022
Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (
Marta Hernández-García, María García-Castillo, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez-Lozano, Nuria Tormo, José Melo-Cristino, Margarida F. Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui Ferreira, Hugo Cruz, Catarina Chaves, Joana Duarte, Leonor Pássaro, Jazmín Díaz-Regañón, Rafael Cantón   +23 more
doaj   +4 more sources

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates [PDF]

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +3 more sources

Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia. [PDF]

Antibiotics (Basel)
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant therapeutic challenge, particularly when multiple resistance mechanisms, such as metallo-β-lactamases (MBLs) and Klebsiella pneumoniae carbapenemase (KPC), coexist.
Pipitò L, Rubino R, Immordino R, Bono E, Fasciana T, Bonura C, Giammanco GM, Argano V, Cascio A.   +8 more
europepmc   +2 more sources

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

International Journal of Infectious Diseases, 2019
Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin.
Pratik Bhagunde, Katherine Young
exaly   +3 more sources

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +2 more sources

Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE). [PDF]

Antimicrob Agents Chemother
Imipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa, but real-world effectiveness data are limited.
Wangchinda W, Wu JY, Abbo LM, Ackley R, Bartley P, Gilboa M, Harrington J, Jaffa R, Klatt ME, Kline EG, Kubat RC, Lepak AJ, McCreary EK, Miller WR, Pearson JC, Shah S, Tran TT, Vega A, Vendetti M, Yucel E, Pogue JM, Shields RK.   +21 more
europepmc   +2 more sources